Diagnosis and treatment of endometriosis and related conditions
The technology described herein relates to KIM-1 and the diagnosis, prognosis, and treatment of endometrial diseases and disorders.
1. A method of administering a treatment for a condition selected from the group consisting of:
endometriosis; endometriotic cysts; or endometrioid cancer;
to a subject, the method comprising
administering the treatment for the condition to a subject determined to have a level of kidney injury molecule 1 (KIM-1) in a urine test sample obtained from the subject which is greater than 500 pg of KIM-1 polypeptide per mg of urinary creatinine.
2. The method of claim 1 , the method further comprising a step of determining that the subject has normal kidney function.
3. The method of claim 2 , wherein the step of determining that the subject has normal kidney function comprises a kidney function urinalysis or kidney function blood test.
4. The method of claim 1 , wherein the treatment is selected from the group consisting of:
a hormonal treatment; progesterone; progestin; an oral contraceptive; a hormonal contraceptive; danocrine; gentrinone; a gonadotrophin releasing hormone agonist; Lupron; danazol; an aromatase inhibitor; pentoxifylline; surgical treatment; laparoscopy; cauterization; and cystectomy.
5. The method of claim 1 , wherein the level of KIM-1 is determined by measuring the level of KIM-1 polypeptide.
6. The method of claim 5 , wherein the KIM-1 polypeptide comprises the ectodomain of KIM-1 polypeptide.
7. The method of claim 1 , wherein the endometriosis has or is at risk of progressing to a condition selected from the group consisting of:
endometriotic cyst; ovarian carcinoma; and clear cell ovarian cancer.